BR8907518A - Processo para inibir a atividade do virus da imunodeficiencia humana(hiv)in vivo - Google Patents
Processo para inibir a atividade do virus da imunodeficiencia humana(hiv)in vivoInfo
- Publication number
- BR8907518A BR8907518A BR898907518A BR8907518A BR8907518A BR 8907518 A BR8907518 A BR 8907518A BR 898907518 A BR898907518 A BR 898907518A BR 8907518 A BR8907518 A BR 8907518A BR 8907518 A BR8907518 A BR 8907518A
- Authority
- BR
- Brazil
- Prior art keywords
- hiv
- activity
- immunodeficiency virus
- vivo
- human immunodeficiency
- Prior art date
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title abstract 6
- 230000000694 effects Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 239000003430 antimalarial agent Substances 0.000 abstract 3
- 238000001727 in vivo Methods 0.000 abstract 3
- XEEQGYMUWCZPDN-DOMZBBRYSA-N (-)-(11S,2'R)-erythro-mefloquine Chemical compound C([C@@H]1[C@@H](O)C=2C3=CC=CC(=C3N=C(C=2)C(F)(F)F)C(F)(F)F)CCCN1 XEEQGYMUWCZPDN-DOMZBBRYSA-N 0.000 abstract 1
- 150000005011 4-aminoquinolines Chemical class 0.000 abstract 1
- 150000005012 8-aminoquinolines Chemical class 0.000 abstract 1
- 150000005027 9-aminoacridines Chemical class 0.000 abstract 1
- 229940123208 Biguanide Drugs 0.000 abstract 1
- FOHHNHSLJDZUGQ-VWLOTQADSA-N Halofantrine Chemical compound FC(F)(F)C1=CC=C2C([C@@H](O)CCN(CCCC)CCCC)=CC3=C(Cl)C=C(Cl)C=C3C2=C1 FOHHNHSLJDZUGQ-VWLOTQADSA-N 0.000 abstract 1
- 241000282412 Homo Species 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 229930013930 alkaloid Natural products 0.000 abstract 1
- 150000004283 biguanides Chemical class 0.000 abstract 1
- 230000005540 biological transmission Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 229960003242 halofantrine Drugs 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 229960001962 mefloquine Drugs 0.000 abstract 1
- 230000001681 protective effect Effects 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 229930009674 sesquiterpene lactone Natural products 0.000 abstract 1
- 150000002107 sesquiterpene lactone derivatives Chemical class 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
- 150000003456 sulfonamides Chemical class 0.000 abstract 1
- 150000003457 sulfones Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
- A61K31/10—Sulfides; Sulfoxides; Sulfones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/49—Cinchonan derivatives, e.g. quinine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US21382288A | 1988-06-30 | 1988-06-30 | |
| PCT/US1989/002586 WO1990000055A1 (en) | 1988-06-30 | 1989-06-19 | Method of inhibiting the activity of human immunodeficiency virus (hiv) in vivo |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR8907518A true BR8907518A (pt) | 1991-05-28 |
Family
ID=22796649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR898907518A BR8907518A (pt) | 1988-06-30 | 1989-06-19 | Processo para inibir a atividade do virus da imunodeficiencia humana(hiv)in vivo |
Country Status (9)
| Country | Link |
|---|---|
| EP (1) | EP0422097B1 (pt) |
| JP (1) | JPH03505579A (pt) |
| KR (1) | KR920008704B1 (pt) |
| AT (1) | ATE104851T1 (pt) |
| AU (1) | AU633499B2 (pt) |
| BR (1) | BR8907518A (pt) |
| DE (1) | DE68914990T2 (pt) |
| RU (2) | RU2060032C1 (pt) |
| WO (1) | WO1990000055A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5668149A (en) * | 1990-01-26 | 1997-09-16 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibition of human immunodeficiency virus-1 infectivity in human cells |
| WO1992006683A1 (en) * | 1990-10-22 | 1992-04-30 | Research Corporation Technologies, Inc. | Aryl and heteroaryl compounds having anti-retrovirus activity |
| AU2279292A (en) * | 1991-07-15 | 1993-02-23 | Smithkline Beecham Plc | Pharmaceutical formulations comprised of micronised halofantrine |
| GB0021776D0 (en) * | 2000-09-05 | 2000-10-18 | Arakis Ltd | The treatment of inflammatory disorders |
| ITBO20020416A1 (it) * | 2002-06-28 | 2003-12-29 | Valpharma Sa | Uso della clorochina, idrossi-clorochina e derivati 4 amino-chinolinici per l'ottenimento di un farmaco per la terapia anti retrovirale atti |
| US7772284B2 (en) * | 2003-08-27 | 2010-08-10 | Labib Mohamed E | Method for the treatment or prevention of virus infection using polybiguanide-based compounds |
| FR2891744B1 (fr) * | 2005-10-06 | 2009-10-09 | France Etat Armement | Application a la chimioprophylaxie du paludisme d'une association de chloroquine et de doxycycline |
| DK2950649T3 (da) * | 2013-02-01 | 2020-05-04 | Wellstat Therapeutics Corp | Aminforbindelser med antiinflammations-, antisvampe-, antiparasit- og anticanceraktivitet |
| US20220062281A1 (en) * | 2018-08-13 | 2022-03-03 | National Centre For Biological Sciences-Tifr | Inhibitors to target hiv-1 nef-cd80/cd86 interactions for therapeutic intervention |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3005755A (en) * | 1956-03-30 | 1961-10-24 | Endo Lab | Aqueous solutions of quinidine salts and nicotinamide |
| AU596272B2 (en) * | 1987-02-25 | 1990-04-26 | Trustees Of Columbia University In The City Of New York, The | Method of inhibiting the transmission of aids virus |
| JPH01221364A (ja) * | 1988-01-11 | 1989-09-04 | Microbial Chem Res Found | Ｈｉｖ逆転写酵素阻害剤および抗腫瘍剤 |
-
1989
- 1989-06-19 JP JP1507352A patent/JPH03505579A/ja active Pending
- 1989-06-19 EP EP89907892A patent/EP0422097B1/en not_active Expired - Lifetime
- 1989-06-19 AU AU38529/89A patent/AU633499B2/en not_active Ceased
- 1989-06-19 WO PCT/US1989/002586 patent/WO1990000055A1/en active IP Right Grant
- 1989-06-19 BR BR898907518A patent/BR8907518A/pt not_active Application Discontinuation
- 1989-06-19 KR KR1019900700426A patent/KR920008704B1/ko not_active IP Right Cessation
- 1989-06-19 AT AT8989907892T patent/ATE104851T1/de not_active IP Right Cessation
- 1989-06-19 DE DE68914990T patent/DE68914990T2/de not_active Expired - Fee Related
- 1989-06-19 RU SU894894541A patent/RU2060032C1/ru not_active IP Right Cessation
- 1989-06-19 RU RU94045248A patent/RU2145856C1/ru not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| AU633499B2 (en) | 1993-02-04 |
| KR920008704B1 (ko) | 1992-10-08 |
| RU2145856C1 (ru) | 2000-02-27 |
| DE68914990T2 (de) | 1994-08-11 |
| ATE104851T1 (de) | 1994-05-15 |
| RU2060032C1 (ru) | 1996-05-20 |
| DE68914990D1 (de) | 1994-06-01 |
| EP0422097A4 (en) | 1992-03-11 |
| EP0422097B1 (en) | 1994-04-27 |
| RU94045248A (ru) | 1996-08-20 |
| EP0422097A1 (en) | 1991-04-17 |
| KR900701271A (ko) | 1990-12-01 |
| WO1990000055A1 (en) | 1990-01-11 |
| AU3852989A (en) | 1990-01-23 |
| JPH03505579A (ja) | 1991-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX9203543A (es) | Medicamento. | |
| EP0270317A3 (en) | Pharmaceutical compositions for the treatment of diseases caused by viruses | |
| NL990001I2 (nl) | Geneesmiddel, dat dipyridamol of modipamol en O-acetylsailcylzuur resp. fysiologisch verdraagbare zouten daarvan, bevat, werkwijze voor de bereiding daarvan en toepassing daarvan voor het bestrijden van thrombusvorming. | |
| BR8907518A (pt) | Processo para inibir a atividade do virus da imunodeficiencia humana(hiv)in vivo | |
| PT91524A (pt) | Processo de preparacao de um medicamento a base de fraccoes e/ou fragmentos de heparina | |
| Bunnag et al. | Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria | |
| EP0230574A3 (en) | Pharmaceutical compositions against infections caused by lav/htlv iii virus and the use thereof | |
| Bunnag et al. | Double blind randomised clinical trial of two different regimens of oral artesunate in falciparum malaria | |
| Powell et al. | Studies on a strain of chloroquine-resistant Plasmodium falciparum from Viet-Nam | |
| AR002029A1 (es) | Composicion farmaceutica, procedimiento para su manufactura, y metodos para la manufactura de medicamentos que la contienen | |
| Bruce-Chwatt | Classification of antimalarial drugs in relation to different stages in the life-cycle of the parasite: commentary on a diagram | |
| PT89266A (pt) | Metodo para a inibicao de virus da imunodeficiencia humana utilizando um derivado n-n-butilo de desoxinojirimicina | |
| MC1930A1 (fr) | Produit antiviral | |
| Coatney et al. | Primaquine and quinocide as curative agents against sporozoite-induced Chesson strain vivax malaria | |
| CA2032748A1 (en) | Method of inhibiting the activity of human immunodeficiency virus (hiv) in vivo | |
| WO1990005523A3 (en) | Phenanthrolinedicarboxylate esters, 4-aminoquinoline and isoquinoline derivatives as inhibitors of hiv reverse transcriptase | |
| SE8804640D0 (sv) | Medicament comprising cyclolinopeptide a | |
| Sweeney et al. | Efficacy of mefloquine against malaria parasites in animal models | |
| Laboratory | Preliminary studies on tripiperaquine (M 1020) | |
| Folkers et al. | Therapy with coenzyme Q. sub. 10 of patients having AIDS or other retroviral diseases | |
| Jian-ping et al. | A comparative study of dihydroartemisinin compounds in treatment of uncomplicated falciparum malaria in Kampong of Cambodia | |
| Batterman et al. | ANGINAL SYNDROME—Treatment with a Long-Acting Nitrate (Itramin Tosylate) | |
| Wernsdorfer | The changing role of drugs in malaria control | |
| DE68908757T2 (de) | 5-Methoxypsoralen gegen Depressionen. | |
| ZWICKER | MALARIA IN A RETURNED KOREAN WAR VETERAN |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EG | Technical examination (opinion): publication of technical examination (opinion) | ||
| FC | Decision: refusal |